{"schema_version":"secwatch.filing_event.v1","accession":"0000711404-23-000068","form_type":"8-K","ticker":"COO","cik":"0000711404","company_name":"COOPER COMPANIES, INC.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.786098+00:00","generated_at":"2026-06-07T16:35:34.347735+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cooper Q4 revenue $927M (+9%); FY2024 guidance $3.81-3.88B; 4-for-1 stock split","bullets":["Q4 GAAP diluted EPS $1.70 (+29%); non-GAAP diluted EPS $3.47 (+26%). FY GAAP EPS $5.91 (-24%), non-GAAP $12.81 (+3%).","CooperVision Q4 revenue $622.9M (+11% YoY) led by toric (+18%) and multifocal (+22%) lenses.","CooperSurgical Q4 revenue $304.2M (+6%), fertility up 12%.","FY2024 guidance: revenue $3.809-3.877B; non-GAAP EPS $13.60-14.00.","Board approved 4-for-1 stock split (effective Feb 16, 2024) and will end de minimis semi-annual dividend."],"urls":{"canonical":"https://secwatch.observer/filing/0000711404-23-000068","json":"https://secwatch.observer/filing/0000711404-23-000068.json","markdown":"https://secwatch.observer/filing/0000711404-23-000068.md","text":"https://secwatch.observer/filing/0000711404-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/711404/000071140423000068/0000711404-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/711404/000071140423000068/coo-20231206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:35:34.347735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18bee057315f0ececfed01c64f6dc4b73b53fa54","claim":"COOPER COMPANIES, INC. reported fiscal year 2024 results: revenue $3,809 - $3,877 million, EPS $13.60 - $14.00 (non-GAAP diluted EPS). Guidance initiated.","evidence_excerpt":"The Company initiated its fiscal year 2024 financial guidance. Details are summarized as follows: • Fiscal 2024 total revenue of $3,809 - $3,877 million (organic growth of 6% to 8%) • CVI revenue of $2,548 - $2,594 million (organic growth of 7% to 9%) • CSI revenue of $1,261 - $1,283 million (organic growth of 4% to 6%) • Fiscal 2024 non-GAAP diluted earnings per share of $13.60 - $14.00","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711404/000071140423000068/0000711404-23-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2024"},{"label":"Revenue","value":"$3,809 - $3,877 million"},{"label":"EPS","value":"$13.60 - $14.00 (non-GAAP diluted EPS)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"2be36edea3d05421e2f0d79dc25bc7e68a00ea36","claim":"COOPER COMPANIES, INC. reported fiscal 2023 full year ended October 31, 2023 results: revenue $3,593.2 million.","evidence_excerpt":"CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2023. • Fourth quarter 2023 revenue of $927.1 million, up 9%, and up 9% organically. Fiscal year 2023 revenue of $3.6 billion, up 9%, or up 10% organically. • Fourth quarter 2023 GAAP diluted earnings per share (EPS) of $1.70, up 29%. Fiscal 2023 GAAP diluted EPS of $5.91, down 24%. • Fourth quarter 2023 non-GAAP diluted EPS of $3.47, up 26%. Fiscal 2023 non-GAAP diluted EPS of $12.81, up 3%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711404/000071140423000068/0000711404-23-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023 full year ended October 31, 2023"},{"label":"Revenue","value":"$3,593.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5ac3d76144360bc9144826e9059fb17bbaebc62d","claim":"COOPER COMPANIES, INC. reported fiscal Q4 2023 ended October 31, 2023 results: revenue $927.1 million, EPS $1.70 (GAAP diluted EPS), $3.47 (non-GAAP diluted EPS).","evidence_excerpt":"a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2023. • Fourth quarter 2023 revenue of $927.1 million, up 9%, and up 9% organically. Fiscal year 2023 revenue of $3.6 billion, up 9%, or up 10% organically. • Fourth quarter 2023 GAAP diluted earnings per share (EPS) of $1.70, up","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/711404/000071140423000068/0000711404-23-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal Q4 2023 ended October 31, 2023"},{"label":"Revenue","value":"$927.1 million"},{"label":"EPS","value":"$1.70 (GAAP diluted EPS), $3.47 (non-GAAP diluted EPS)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}